As generic competition stutter sales of top oncology drugs, Roche secures speedy review for pair of experimental cancer offerings

As generic competition stutter sales of top oncology drugs, Roche secures speedy review for pair of experimental cancer offerings

Source: 
Endpoints
snippet: 

As drug developers seek ways to expand therapeutic applications and overcome the hurdles seen with the first generation of antibody drug conjugates (ADCs), Roche is capitalizing on its trojan horse ADC — powered by Seattle Genetics’ technology — as generics eat into the sales of its trifecta of top cancer drugs.